Lehrstuhl für Geburtshilfe und Frauenheilkunde


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Phototoxicity of brightfield live-cell imaging on murine ovarian follicles (2026) Stadter M, Dittrich R, Häberle L, Lotz L, Brey S, Bleisinger N, Schmid B, et al. Journal article Breast cancer risk genes affecting individual radiosensitivity (2026) Vogel R, Amann N, Zuhair Kassem T, Gaß P, Mayo T, Woltereck F, Hack C, et al. Journal article Histological evaluation of hysterectomy specimens after NovaSure® endometrial ablation in patients with atypical endometrial hyperplasia or endometrial carcinoma (2026) Schleicher O, Hamzeh A, Gocke J, Pöschke P, Stübs F, Burghaus S, Heindl F, et al. Journal article Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence (2026) Khor CC, Ong WS, Lim EH, Chatelut E, Chen S, Muerdter TE, Abraham JE, et al. Journal article PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry (2026) Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Professional Health Literacy among Midwives - Findings from a Standardised Online Survey Conducted in Bavaria Professionelle Gesundheitskompetenz von Hebammen - Ergebnisse einer standardisierten Online-Befragung in Bayern (2026) Sponsel S, Pfaller L, Karrer L, Schöffski O, Beckmann M, Mocker A Journal article Breast cancer prevention in patients with gBRCA-mutated ovarian cancer (2026) Amann N, Krückel A, Brückner L, Gocke J, Müller C, Heindl F, Hack C, et al. Journal article Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study. (2026) Schmid P, Cortes J, Dent RA, McArthur HL, Pusztai L, Kuemmel S, Denkert C, et al. Journal article The SURVIVE study: Re-evaluating follow-up in early breast cancer. (2026) Huesmann ST, Friedl TW, Pfister K, Schäffler H, Fink A, Braun T, Mehmeti F, et al. Journal article